Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
- Conditions
- Left Bundle Branch PacingHeart Failure
- Interventions
- Drug: GDMTDevice: LBBP+GDMT
- Registration Number
- NCT06126081
- Lead Sponsor
- Fu Wai Hospital, Beijing, China
- Brief Summary
This is a two-center, prospective randomized controlled trial. The aim of this study is to compare the clinical efficacy of early left bundle branch pacing for cardiac resynchronization therapy and guideline-directed medical therapy in heart failure with mild-reduced ejection fraction.
- Detailed Description
Early-resync is a two-center, prospective randomized controlled trial that is designed to determine whether early left bundle branch pacing has a better impact on LV function improvement as compared with traditional guideline-directed medical therapy in heart failure with mild-reduced ejection fraction（36%≤LVEF≤50%） and complete left bundle branch block (CLBBB). Patients with symptomatic heart failure,36%≤LVEF≤50%, NYHA function class II-IV, and CLBBB（according to STRAUSS criteria) will be 1:1 randomized to LBBP+GDMT or GDMT group after enrollment and be followed at 3 and 6 months after randomization. LBBP will be performed by a double-chamber device in LBBP+GDMT group. All patients will receive GDMT. The primary endpoint is the change in the LVEF at 6 months after randomization from baseline.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 36
- Age ≥ 18 years;
- symptomatic heart failure despite guideline-directed medical therapy for at least 3 months, NYHA class II-IV, with an EF between 35% and 50%;
- complete LBBB meeting Strauss's standard definition
- Signed informed consent.
- Expected survival less than 24 months;
- Indicated for ICD or pacing therapy;
- History of VT, VF, or hemodynamic instability;
- History of mechanical tricuspid valve replacement;
- Ischemic cardiomyopathy scheduled for CABG and PCI within 3 months;
- Severe structural heart disease may necessitate cardiac surgery or heart transplantation within 1 year;
- Pregnancy or planning for pregnancy;
- Hypertrophic cardiomyopathy or those underwent ventricular septal defect repair, in whom the success of LBBP is anticipated to be challenging;
- Severe renal dysfunction (eGFR < 15ml/min*1.73m^2).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GDMT group GDMT Patients in the GDMT group will receive guideline-directed medical therapy according to their complications, heart rate, blood pressure and so on. During follow-up of 6 months, patients may transfer to LBBP group if the LVEF decreased to \<35% and patients accepted the device implantation. LBBP+GDMT group LBBP+GDMT Patients in the LBBP+GDMT group will receive LBBP using dual-chamber device as priority and guideline-directed medical therapy. The pacing lead will be implanted at the left bundle branch and whether LBB is captured will be judged during the procedure. For patients who LBBP is failed, CRTP using triple-chamber device or LVSP by using dual-chamber device will be an alternative option according to the co-determination after consultation between doctors and patients .
- Primary Outcome Measures
Name Time Method ΔLVEF between baseline and 6-month follow-up 6 months ΔLVEF：change in LVEF in percentage (%) between baseline and 6-month follow-up
- Secondary Outcome Measures
Name Time Method The rate of LVEF <=35% at six-month 6 months The percentage of patients with LVEF \<=35% at 6 month follow-up
The echocardiographic response rate of LVEF ≥50% 6 months the percentage of patients with LVEF ≥50% at 6 month follow-up
Composite incidence rate of all-cause mortality and/or hospitalization for heart failure 6 months All-cause death: including cardiovascular and non-cardiovascular deaths. Hospitalization for heart failure: an unplanned outpatient or emergency department visit or inpatient hospitalization in which the patient presented with signs and symptoms consistent with heart failure and required medication therapy.
The changes of 6MWD between baseline and 6-month follow-up. 6 months 6MWD in meters stands for "6-Minute Walk Distance." It is a common test used to assess a person's functional exercise capacity and cardiovascular endurance. During the test, the patient is asked to walk as far as possible within a span of 6 minutes in a straight path or designated walking course;
ΔLVEDD and ΔLVESV between baseline and 6-month follow-up 6 months ΔLVEDD：change in LVEDD in millimeters between baseline and 6-month follow-up between two groups.
ΔLVESV：change in LVESV in milliliters between baseline and 6-month follow-up between two groups.The changes of NT-proBNP between baseline and 6-month follow-up. 6 months NT-proBNP in pg/ml was measured by performing a blood test;
The changes of NYHA function class between baseline and 6-month follow-up. 6 months NYHA function class (from I to IV) is evaluated by clinicians at each outpatient follow-up visit;
The changes of QoL between baseline and 6-month follow-up. 6 months QoL stands for "Quality of Life", which is measured by The Minnesota Living with Heart Failure Questionnaire (MLHFQ). The MLHFQ is a self-administered disease-specific questionnaire for patients with HF, comprising 21 items from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL).
Trial Locations
- Locations (2)
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China
The first affiliated hospital of Nanjing medical university
🇨🇳Nanjing, Jiangsu, China